Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Talabostat in advanced melanoma
NCT00083239Phase 2Completed
- Sponsor
- Point Therapeutics
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of talabostat in melanoma, sponsored by Point Therapeutics. Status: completed.
02
Drugs
talabostat
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT00083239.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00083239.